Pasithea Therapeutics Corp. (KTTA) - P/E Multiple
Pasithea Therapeutics (KTTA) bases its business on managing a network of centers that utilize ketamine infusion to treat depression and chronic pain. The company's operations are exposed to risks of supply chain disruptions for rare reagents and delays in global software testing. Historical price action on GURU.Markets shows a value of -0.70, while the staff of leading neurobiologists remains stable and committed to scientific goals.
Comprehensive metric breakdowns and analytics for pasitheaclinics.com (KTTA)
- stock price and consensus target price:
- market capitalization indicators:
- company book value details:
- company liabilities and liquidity data:
Aggregate Debt to Capital Pasithea Therapeutics|KTTA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Pasithea Therapeutics|KTTA - Company Aggregate Debts|Debts to Book Value Pasithea Therapeutics Corp|KTTA - Company Long-Term Debts|Company Short-Term Debts Pasithea Therapeutics|Intermediate Coverage Ratio pasitheaclinics.com
- earnings and market multiples details:
KTTA - Net Income|Future Net Profit Pasithea Therapeutics|KTTA - P/E Multiple|Future Price to Earnings Multiple Pasithea Therapeutics|KTTA - PEG Multiple|Company Value to EBITDA Pasithea|KTTA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Pasithea Therapeutics|KTTA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth pasitheaclinics.com|KTTA - Earnings per share growth in current year|Net earnings per share change forecast for next year Pasithea Therapeutics
- company sales and revenue statistics:
Summary company analysis:KTTA (Pasithea Therapeutics Corp.)
Pasithea Therapeutics (KTTA) is optimizing biocomponent supply chains for the development of psychiatric disorder treatments. The ratio of market capitalization to net income, reflected in the company's P/E ratio dynamics, measures the premium for the future success of clinical trials. This coefficient demonstrates investors' willingness to pay a premium per unit of current earnings. This chart allows for the differentiation of accounting metrics from the asset's real value, which determines the fair cost of capital under high-risk conditions.
Key competitors
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|ALZN - P/E Multiple|Cyclerion (CYCN) - Price to Earnings Ratio|Protagenic (PTIX) - P/E Multiple|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
